News
FDA recalls ranitidine medicines over potential cancer causing impurity
BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l5832 (Published 02 October 2019) Cite this as: BMJ 2019;367:l5832- Elisabeth Mahase
- The BMJ
The US Food and Drug Administration has asked doctors and patients to return certain batches of over-the-counter ranitidine tablets (75 mg and 150 mg), after low levels of the probable human carcinogen N-nitrosodimethylamine (NDMA) were detected.1
The FDA released updates to the public and doctors explaining that some ranitidine medicines might contain low levels of NDMA and asked for any tablets labelled by Walgreens, Walmart, or Rite-Aid …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.